Acelyrin claims errors by CRO Fortrea led to late-stage trial downfall
A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint

A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint
Boehringer will utilise a generative AI model developed by IBM to discover candidate antibodies.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Japan approves Daiichi Sankyo’s Covid-19 booster vaccine
IGC Pharma signs agreement to adopt AI solutions into drug discovery
Genentech and NVIDIA enter generative AI-powered drug discovery deal
Daiichi Sankyo signs agreement with Japan to supply Covid-19 vaccine